Navigation Links
Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
Date:3/20/2012

SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab. The two-arm, dose-escalation study will evaluate JX-594 as a monotherapy and in combination with irinotecan.

The multicenter study will be conducted in the United States, Canada and Europe and is designed to enroll up to 42 patients. Patients will be enrolled in one of two treatment groups—one treatment group will receive JX-594 as a monotherapy and one treatment group will receive JX-594 in combination with irinotecan. Patients in both groups will receive five weekly intravenous infusions of JX-594 at one of two escalating dose levels followed by up to three optional intratumoral injections of JX-594 into metastases to the liver. The combination group will receive concomitant administrations of irinotecan. Once the maximum tolerated dose is determined for each treatment group, additional patients will be enrolled at that dose level. The endpoints of the trial include safety, dose optimization, and tumor responses as measured by RECIST and Choi criteria. For more information about the trial, please visit www.clinicaltrials.gov.

"JX-594, with its three diverse, anticancer mechanisms of action, has shown very strong clinical data to date against multiple tumor types, and it is currently being evaluated in clinical trials for advanced liver and colorectal cancers," said David H. Kirn, M.D., president and chief medical officer of Jennerex. "In the clinical trial announced today, we are particularly interested in o
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 According to a ... & 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary ... by Application & by End User - Global Forecast ... expected to reach around $1.98 Billion by 2020 with ... to 2020. Browse 226 ma ...
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2
... , LONDON, November 9 ... US Food and Drug Administration (FDA), privately,owned UK company ... its innovative,anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug,designation ... ALS, also known as Lou ...
... , LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. ... collagenase-based products, today announced its financial results for the ... were extremely happy that, in September of this year, ... vote of 12-0, the approval of XIAFLEX(TM) for the ...
... announced today that it has been awarded a Small Business ... Medical Research and Material command. Under terms of the agreement, ... of Dengue virus. , Dengue virus is ... forces deployed to tropical areas of the world. Due to ...
Cached Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... in partnership with Rothamsted Research have officially joined forces ... how can we sustainably feed a growing population? ... the House of Commons on 26 October amidst reports ... reaching seven billion. The Alliance brings together world-class ...
... 28 2011 the research icebreaker Polarstern sets off on ... from research institutions in 14 countries will take part ... wide variety of topics: oceanography and marine chemistry, atmospheric ... animals all the way to crustaceans, fish and whales. ...
... luxuriously thick winter coat, reindeer are perfectly prepared for the ... just keep the cold out, it keeps the warmth in ... what happens when they are active and generating heat? Usain ... do exercising reindeer avoid overheating? Arnoldus Blix from the University ...
Cached Biology News:UK scientists come together to help feed the 7 billion 2UK scientists come together to help feed the 7 billion 3UK scientists come together to help feed the 7 billion 4UK scientists come together to help feed the 7 billion 5RV Polarstern launches 28th Antarctic season 2Rudolph the red-nosed reindeer's cooling strategy revealed 2
... SMZ line is a Greenough stereomicroscope designed for ... is available with a choice of a large ... base (N2GG). This microscope can be easily connected ... at the same time giving you ultimate flexibility. ...
... siRNA applications, contains magnetic nanoparticles (MagTag) which ... of interest. Exploiting magnetic force the full ... towards and delivered into the target cells ... be used for adherent cells; for suspension ...
...
... TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) offer ... vitro translations: a single-tube, coupled transcription/translation ... simplify the process and reduce the ... translation results. Standard rabbit reticulocyte lysate ...
Biology Products: